FDA Finds ‘Extremely High’ Lead Levels In Cinnamon Used In Tainted Fruit Pouches
The cinnamon, which originated from a plant in Ecuador, had lead levels more than 2,000 times higher than a maximum level proposed by the FDA, officials said.
Similar Posts
Finding happiness after the Clutha helicopter crash
It’s a decade since a police helicopter crashed through the roof of the Clutha Bar in Glasgow. Among those there that Friday night was Michael Byrne. He helped pull survivors from the rubble at the city centre bar, where 10 people lost their lives. Although Michael managed to escape without injury, the emotional impact the…
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….
Screen time for kids under age 2 is linked to sensory differences in toddlerhood, new study finds
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Healthcare software vendor NextGen explores sale | Reuters News Agency
Business & FinanceDealsHealth 23 August 2023, 2:10 pm 1 minute Reuters exclusively reported that NextGen Healthcare (NXGN.O), a provider of software that helps manage patients’ records, is exploring options that include a sale of the company. Market Impact NextGen shares rose 10% to $18.01 on the news in afternoon trading in New York on Wednesday,…
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…
Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…
